NOT-GM-23-047: Notice of Change to the Composition of the Advisory Committee in PAR-23-063 "Limited Competition: Renewal of Centers of Biomedical Research Excellence (COBRE) (Phase 2) (P20

Notice of Change to the Composition of the Advisory Committee in PAR-23-063 "Limited Competition: Renewal of Centers of Biomedical Research Excellence (COBRE) (Phase 2) (P20 - Clinical Trial Optional)"

Notice Number:

NOT-GM-23-047

Key Dates

Release Date:

July 12, 2023

Related Announcements

December 20, 2022 - Limited Competition: Renewal of Centers of Biomedical Research Excellence (COBRE) (Phase 2) (P20 - Clinical Trial Optional). See NOFO PAR-23-063.

Issued by

National Institute of General Medical Sciences (NIGMS)

Purpose

The purpose of this Notice is to modify the requirements for the composition of the Advisory Committee (AC) for COBRE Phase 2 awards. Applications submitted in response to PAR-23-063 will be able to retain all active members of their Phase 1 COBRE External Advisory Committee (EAC) as AC members for the Phase 2 award. The following section of the Notice of Funding Opportunity (NOFO) is changed accordingly.

Part 2. Section IV.2 Content and Form of Application Submission

Overall Component

PHS 398 Research Plan (Overall)

The Research Strategy section currently reads:

C. Plan for an Advisory Committee

An Advisory Committee (AC) composed of three external, nationally recognized scientists with expertise directly relevant to the scientific area of the Center, one senior institutional official (e.g., Dean, Vice-President for Research), and one senior faculty member appointed by the senior institutional official must be assembled to advise the PD(s)/PI(s). AC members who previously served as external advisors during Phase 1 may be appointed as Phase 2 AC members. An AC member may not serve as an RPL mentor, core director/advisor, or hold any other position in the Center.

The Research Strategy section is modified to read (changes noted in italics):

C. Plan for an Advisory Committee

An Advisory Committee (AC) composed of at least three external, nationally recognized scientists with expertise directly relevant to the scientific area of the Center, a senior institutional official (e.g., Dean, Vice-President for Research), and a senior faculty member appointed by the senior institutional official must be assembled to advise the PD(s)/PI(s). Applicants may retain all active members of their Phase 1 External Advisory Committee (EAC) in the Phase 2 application. An AC member may not serve as an RPL mentor, core director/advisor, or hold any other position in the Center.

All other aspects of the NOFO remain the same.

Inquiries

Please direct all inquiries to:

Federico Bernal, PhD
National Institute of General Medical Sciences (NIGMS)
Email: federico.bernal@nih.gov